Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.

Hamblett KJ, Le T, Rock BM, Rock DA, Siu S, Huard JN, Conner KP, Milburn RR, O'Neill JW, Tometsko ME, Fanslow WC.

Mol Pharm. 2016 Jul 5;13(7):2387-96. doi: 10.1021/acs.molpharmaceut.6b00153. Epub 2016 Jun 13.

PMID:
27248573
2.

SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.

Hamblett KJ, Jacob AP, Gurgel JL, Tometsko ME, Rock BM, Patel SK, Milburn RR, Siu S, Ragan SP, Rock DA, Borths CJ, O'Neill JW, Chang WS, Weidner MF, Bio MM, Quon KC, Fanslow WC.

Cancer Res. 2015 Dec 15;75(24):5329-40. doi: 10.1158/0008-5472.CAN-15-1610. Epub 2015 Dec 2.

3.

Intracellular Catabolism of an Antibody Drug Conjugate with a Noncleavable Linker.

Rock BM, Tometsko ME, Patel SK, Hamblett KJ, Fanslow WC, Rock DA.

Drug Metab Dispos. 2015 Sep;43(9):1341-4. doi: 10.1124/dmd.115.064253. Epub 2015 Jun 22.

PMID:
26101225
4.

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.

Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, Trueblood ES, Meininger D, Arora T, Twomey B, Vonderfecht SL, Chen Q, Hill JS, Fanslow WC.

Mol Cancer Ther. 2015 Jul;14(7):1614-24. doi: 10.1158/1535-7163.MCT-14-1078. Epub 2015 Apr 30.

5.

Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor.

Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK.

J Immunol. 2011 Nov 1;187(9):4392-402.

6.

Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability.

Morrissey C, Dowell A, Koreckij TD, Nguyen H, Lakely B, Fanslow WC, True LD, Corey E, Vessella RL.

Prostate. 2010 Dec 1;70(16):1799-808. doi: 10.1002/pros.21216.

7.

Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule.

Galibert L, Diemer GS, Liu Z, Johnson RS, Smith JL, Walzer T, Comeau MR, Rauch CT, Wolfson MF, Sorensen RA, Van der Vuurst de Vries AR, Branstetter DG, Koelling RM, Scholler J, Fanslow WC, Baum PR, Derry JM, Yan W.

J Biol Chem. 2005 Jun 10;280(23):21955-64. Epub 2005 Mar 21.

8.

Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax.

Szocinski JL, Khaled AR, Hixon J, Halverson D, Funakoshi S, Fanslow WC, Boyd A, Taub DD, Durum SK, Siegall CB, Longo DL, Murphy WJ.

Blood. 2002 Jul 1;100(1):217-23.

PMID:
12070030
9.

A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis.

Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA, Fanslow WC.

Immunity. 2001 Nov;15(5):837-46.

10.

Identification of CD7 as a cognate of the human K12 (SECTM1) protein.

Lyman SD, Escobar S, Rousseau AM, Armstrong A, Fanslow WC.

J Biol Chem. 2000 Feb 4;275(5):3431-7.

11.

Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions.

Chen AI, McAdam AJ, Buhlmann JE, Scott S, Lupher ML Jr, Greenfield EA, Baum PR, Fanslow WC, Calderhead DM, Freeman GJ, Sharpe AH.

Immunity. 1999 Dec;11(6):689-98.

12.

Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand.

Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG, Agathanggelou A, Cullen N, Macartney J, Fanslow WC, Murphy WJ.

Blood. 1999 May 1;93(9):2999-3007.

PMID:
10216096
13.

Evidence for a role of IL-17 in alloimmunity: a novel IL-17 antagonist promotes heart graft survival.

Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB, Thomson AW.

Transplant Proc. 1999 Feb-Mar;31(1-2):93. No abstract available.

PMID:
10083023
14.

Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells.

Pound JD, Challa A, Holder MJ, Armitage RJ, Dower SK, Fanslow WC, Kikutani H, Paulie S, Gregory CD, Gordon J.

Int Immunol. 1999 Jan;11(1):11-20.

PMID:
10050669
15.

Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors.

Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB, Thomson AW.

J Immunol. 1999 Jan 1;162(1):577-84.

16.

CD40 stimulation promotes human secondary immunoglobulin responses in HuPBL-SCID chimeras.

Murphy WJ, Funakoshi S, Fanslow WC, Rager HC, Taub DD, Longo DL.

Clin Immunol. 1999 Jan;90(1):22-7.

PMID:
9884349
17.

Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154).

Morris AE, Remmele RL Jr, Klinke R, Macduff BM, Fanslow WC, Armitage RJ.

J Biol Chem. 1999 Jan 1;274(1):418-23.

18.

The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo.

Niimi M, Pearson TC, Larsen CP, Alexander DZ, Hollenbaugh D, Aruffo A, Linsley PS, Thomas E, Campbell K, Fanslow WC, Geha RS, Morris PJ, Wood KJ.

J Immunol. 1998 Nov 15;161(10):5331-7.

19.

CD40-mediated signal transduction in human airway smooth muscle.

Lazaar AL, Amrani Y, Hsu J, Panettieri RA Jr, Fanslow WC, Albelda SM, Puré E.

J Immunol. 1998 Sep 15;161(6):3120-7.

20.

CD40 ligand is not essential for the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis.

Campos-Neto A, Ovendale P, Bement T, Koppi TA, Fanslow WC, Rossi MA, Alderson MR.

J Immunol. 1998 Mar 1;160(5):2037-41.

21.

Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome.

Ameratunga R, Lederman HM, Sullivan KE, Ochs HD, Seyama K, French JK, Prestidge R, Marbrook J, Fanslow WC, Winkelstein JA.

J Pediatr. 1997 Jul;131(1 Pt 1):147-50.

PMID:
9255207
22.

Terminology changes needed for descriptions of Pneumocystis carinii infection.

Schuh JC, Harrington KA, Fanslow WC.

Infect Immun. 1997 Mar;65(3):1135-6. No abstract available.

23.

Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice.

Funakoshi S, Taub DD, Anver MR, Raziuddin A, Asai O, Reddy V, Rager H, Fanslow WC, Longo DL, Murphy WJ.

J Clin Invest. 1997 Feb 1;99(3):484-91.

24.
25.

CD40 ligand is required for protective cell-mediated immunity to Leishmania major.

Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR.

Immunity. 1996 Mar;4(3):283-9.

26.
27.

bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice.

Grillot DA, Merino R, Pena JC, Fanslow WC, Finkelman FD, Thompson CB, Nunez G.

J Exp Med. 1996 Feb 1;183(2):381-91.

28.

CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages.

Kennedy MK, Picha KS, Fanslow WC, Grabstein KH, Alderson MR, Clifford KN, Chin WA, Mohler KM.

Eur J Immunol. 1996 Feb;26(2):370-8.

PMID:
8617306
29.

Transforming growth factor-beta 1 cooperates with anti-immunoglobulin for the induction of apoptosis in group I (biopsy-like) Burkitt lymphoma cell lines.

MacDonald I, Wang H, Grand R, Armitage RJ, Fanslow WC, Gregory CD, Gordon J.

Blood. 1996 Feb 1;87(3):1147-54.

PMID:
8562941
30.

Human IL-17: a novel cytokine derived from T cells.

Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ.

J Immunol. 1995 Dec 15;155(12):5483-6.

PMID:
7499828
31.

Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor.

Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK.

Immunity. 1995 Dec;3(6):811-21.

32.
34.

Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes.

Murphy WJ, Funakoshi S, Beckwith M, Rushing SE, Conley DK, Armitage RJ, Fanslow WC, Rager HC, Taub DD, Ruscetti FW, et al.

Blood. 1995 Sep 1;86(5):1946-53.

PMID:
7544649
35.

CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression.

Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS.

Proc Natl Acad Sci U S A. 1995 May 9;92(10):4342-6.

36.

Humoral immune responses in CD40 ligand-deficient mice.

Renshaw BR, Fanslow WC 3rd, Armitage RJ, Campbell KA, Liggitt D, Wright B, Davison BL, Maliszewski CR.

J Exp Med. 1994 Nov 1;180(5):1889-900.

37.

The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization.

Maliszewski CR, Delespesse GJ, Schoenborn MA, Armitage RJ, Fanslow WC, Nakajima T, Baker E, Sutherland GR, Poindexter K, Birks C, et al.

J Immunol. 1994 Oct 15;153(8):3574-83.

PMID:
7930580
38.

CD40 ligand (CD40L) expression and B cell function in agammaglobulinemia with normal or elevated levels of IgM (HIM). Comparison of X-linked, autosomal recessive, and non-X-linked forms of the disease, and obligate carriers.

Callard RE, Smith SH, Herbert J, Morgan G, Padayachee M, Lederman S, Chess L, Kroczek RA, Fanslow WC, Armitage RJ.

J Immunol. 1994 Oct 1;153(7):3295-306.

PMID:
7916370
39.

Structural characteristics of CD40 ligand that determine biological function.

Fanslow WC, Srinivasan S, Paxton R, Gibson MG, Spriggs MK, Armitage RJ.

Semin Immunol. 1994 Oct;6(5):267-78. Review.

PMID:
7532457
40.

In vivo biological effects of recombinant soluble interleukin-4 receptor.

Maliszewski CR, Sato TA, Davison B, Jacobs CA, Finkelman FD, Fanslow WC.

Proc Soc Exp Biol Med. 1994 Jul;206(3):233-7. Review.

PMID:
8016157
41.

Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction.

Klaus SJ, Pinchuk LM, Ochs HD, Law CL, Fanslow WC, Armitage RJ, Clark EA.

J Immunol. 1994 Jun 15;152(12):5643-52.

PMID:
7515910
42.
43.

Inhibition of human B-cell lymphoma growth by CD40 stimulation.

Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I, Armitage RJ, Fanslow WC, Spriggs MK, Murphy WJ.

Blood. 1994 May 15;83(10):2787-94.

PMID:
7514045
44.

Recombinant CD40 ligand exerts potent biologic effects on T cells.

Fanslow WC, Clifford KN, Seaman M, Alderson MR, Spriggs MK, Armitage RJ, Ramsdell F.

J Immunol. 1994 May 1;152(9):4262-9.

PMID:
7908915
45.

CD40 ligand acts as a costimulatory signal for neonatal thymic gamma delta T cells.

Ramsdell F, Seaman MS, Clifford KN, Fanslow WC.

J Immunol. 1994 Mar 1;152(5):2190-7.

PMID:
7510740
46.

Role of interleukin-4 in human immunoglobulin E formation in hu-PBL-SCID mice.

Spiegelberg HL, Beck L, Kocher HP, Fanslow WC, Lucas AH.

J Clin Invest. 1994 Feb;93(2):711-7.

47.

CD40L: a multi-functional ligand.

Armitage RJ, Maliszewski CR, Alderson MR, Grabstein KH, Spriggs MK, Fanslow WC.

Semin Immunol. 1993 Dec;5(6):401-12. Review.

PMID:
7510138
48.

The biology of the human ligand for CD40.

Spriggs MK, Fanslow WC, Armitage RJ, Belmont J.

J Clin Immunol. 1993 Nov;13(6):373-80. Review. No abstract available.

PMID:
7507124
49.

CD40 ligand and its role in X-linked hyper-IgM syndrome.

Callard RE, Armitage RJ, Fanslow WC, Spriggs MK.

Immunol Today. 1993 Nov;14(11):559-64. Review.

PMID:
7506037
50.

Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction.

Holder MJ, Wang H, Milner AE, Casamayor M, Armitage R, Spriggs MK, Fanslow WC, MacLennan IC, Gregory CD, Gordon J, et al.

Eur J Immunol. 1993 Sep;23(9):2368-71.

PMID:
8103750

Supplemental Content

Loading ...
Support Center